Last reviewed · How we verify

NCT04619108

Thrombosomes for Expanded Access Use

NO LONGER AVAILABLE Last updated 21 March 2024
What this trial tests

trial testing Thrombosomes® in Bleeding. No longer available.

Quick facts

Lead sponsorCellphire Therapeutics, Inc.
StatusNO LONGER AVAILABLE
Study typeEXPANDED_ACCESS

Drugs / interventions tested

Conditions studied

Sponsor

Cellphire Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Bleeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Expanded use of Thrombosomes where a clinical trial with Thrombosomes is not an option, Cellphire may elect to provide the Sponsor/Investigator (S/I) expanded access to its investigational product, Thrombosomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Lyophilized platelets inhibit platelet aggregation with simultaneous paradoxical promotion of platelet adhesion.
    Schnoor B, Papa AL. · · 2022 · cited 5× · PMID 36061448 · DOI 10.3389/fbioe.2022.941817

Verify or expand the search:

Other trials of Thrombosomes®

Trials testing the same drug.

Other recruiting trials for Bleeding

Currently open trials in the same condition.

Other Cellphire Therapeutics, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04619108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing